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Abstract
Background: Cholangiocarcinoma (CCA) may arise in the intra- or extrahepatic biliary tract and is associated with a
poor prognosis. Despite recent advances, to date there is still no established targeted therapeutic approach available.
Non-surgical therapeutic agents are urgently needed, as most patients are non-eligible to surgical resection. Anti-PD-L1
therapy prevents cancer cells from evading the immune system and has emerged as a new treatment option in
several cancer entities. Recently, PD-L1 expression has been analyzed in comparably small CCA patient cohorts.
However, a systematic validation of different PD-L1 antibodies has not been performed in CCA so far.
Methods: We stained a tissue microarray consisting of 170 patients, including 72 intrahepatic cholangiocarcinomas
(iCCAs), 57 perihilar cholangiocarcinomas (pCCAs) and 41 distal cholangiocarcinomas (dCCAs) by
immunohistochemistry and evaluated PD-L1 positivity in tumor and stromal cells. We analyzed three different PD-L1
antibodies (clones 28–8, SP142, and SP263) that are frequently used and recommended for predictive diagnostic
testing in other cancer types.
Results: For PD-L1 antibody clone SP263, 5% of iCCAs, 4% of pCCAs and 3% of dCCAs exhibited PD-L1 expression on
tumor cells, thereby showing the highest frequencies of PD-L1 positivity. Accordingly, highest PD-L1 positivity rates of
stromal cells with 31% in iCCA, 40% in pCCA and 61% in dCCA were detected for clone SP263. Agreement of PD-L1
positivity in tumor cells was moderate for clone 28–8 and SP263 (κ = 0.44) and poor between 28-8 and SP142 (κ = 0.13)
, as well as SP142 and SP263 (κ = 0.11), respectively. Statistical analyses of PD-L1 expression (clone SP263) on tumor cells
with clinicopathological data revealed a positive correlation with shortened overall survival in CCA patients.
Conclusions: Selection of appropriate PD-L1 antibodies and careful evaluation of immunohistochemical staining patterns
have a significant impact on PD-L1 testing in CCA. Clinical trials are necessary to investigate the putative beneficial effects
of PD-L1 targeted immunotherapy in CCA patients.
Keywords: PD-L1, Cholangiocarcinoma, CD274, 28–8, SP142, SP263
* Correspondence: Benjamin.goeppert@med.uni-heidelberg.de
1Institute of Pathology, University Heidelberg, Im Neuenheimer Feld 224,
Heidelberg, Germany
7Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kriegsmann et al. BMC Cancer           (2019) 19:72 
https://doi.org/10.1186/s12885-018-5254-0
Background
Recently, a novel class of small molecules was developed
to inhibit the association of programmed cell death ligand
1 (PD-L1) with its receptor programmed cell death pro-
tein 1 (PD-1). PD-L1 is expressed on tumor cells and in-
teracts with PD-1 on cytotoxic T-cells, leading to reduced
T-cell function and thereby lower anti-tumor activity of
the host’s immune system [1]. Thus, PD-L1 inhibitors pre-
vent cancer cells from evading the immune system. These
agents have been found effective in melanoma [2–4],
non-small cell lung cancer [4–6], renal cell carcinoma [4,
7] and urothelial carcinoma [8], and were consequently
approved by the Food and Drug Administration for these
cancer types [9].
Standardized interpretation criteria for predictive PD-L1
testing are still matter of debate, and data of comprehen-
sive and well-characterized cohorts are not available for
rare cancer types [10], including cholangiocarcinoma
(CCA), which is a heterogeneous group of malignancies
that can emerge at any location in the biliary tree, from
the smallest intrahepatic bile ducts (Canaliculi biliferi) to
the distal choledochal duct. According to the anatomical
location, CCAs are subclassified into intrahepatic (iCCA),
perihilar (pCCA), and distal (dCCA) tumors [11]. Al-
though CCAs and biliary tract cancers have often been
treated as one tumor type in the past [12], it is nowadays
widely accepted that CCAs, and in particular intrahepatic
and extrahepatic subtypes display significant clinical, bio-
logical, and therefore therapeutically relevant differences,
leading to the consensus that all subtypes should be
regarded differentially [13, 14]. Clinical studies providing
adequate evidence on the efficacy of PD-L1 therapy in
CCA are not yet available. However, based on the success
in other cancer entities, these agents hold promise in the
therapy of CCA [15]. At present, one of the main chal-
lenges is to select patient subgroups that are likely to
benefit from anti-PD-L1 therapy. Therefore, upfront im-
munohistochemical staining with antibodies against
PD-L1 is recommended to differentiate responders
from non-responders [16]. Moreover, PD-L1 expres-
sion has been shown to correlate with a worse out-
come in a meta-analysis including various cancer
types and more than 16,000 patient samples, but
CCA was not included [17].
Regarding the existing studies, a comprehensive view
of PD-L1 expression in CCA including all subtypes and
correlation with clinicopathological data is not available
to date. Moreover, it has become evident that PD-L1
testing is highly dependent on usage of stringent evalu-
ation criteria and the selection of appropriate PD-L1
antibody clones [18].
In this study, we analyzed PD-L1 expression on tissue
samples of 170 CCA patients using tissue microarrays
(TMAs) to provide a solid database of PD-L1 expression
in Western CCA and its subtypes. Additionally, we com-
pared the staining results of three different PD-L1 anti-
bodies and tested their level of agreement. Furthermore,
we correlated the results of the antibody with the high-
est positivity rates (clone SP263) with clinicopathological
variables including overall survival of CCA patients.
Methods
Cholangiocarcinoma cohort characteristics
Formalin-fixed and paraffin embedded (FFPE) specimens
resected from 1995 to 2010 at Heidelberg University
Hospital were extracted from the archive of the Institute
of Pathology, Heidelberg University, with the support of
the tissue bank of the National Center for Tumor Dis-
eases (NCT; project # 2116). Only resection cases were
included. None of the patients received radio- or chemo-
therapy prior to surgery. Diagnoses were made according
to the World Health Organization (WHO) classification
of Tumors of the Digestive System 2010. Tumors were
restaged according to the 8th UICC/AJCC TNM Classi-
fication Manual by two experienced pathologists. The
CCA cohort consisted only of adenocarcinomas, includ-
ing all histological variants. The cohort consisted of 170
patients including 72 iCCAs, 57 pCCAs, and 41 dCCAs.
Ampullary tumors were not included in this study, as
they are often of intestinal histologic differentiation, and
represent a different tumor entity both, clinically and
biologically. Survival data was available for 141 patients.
Detailed clinicopathological data is displayed in Table 1.
Tissue microarray construction
From all 170 CCA FFPE tissue blocks, 3 μm sections
were cut and stained with H&E. Representative areas
were marked by two experienced pathologists (BG and
SS). In each case, tumor tissue cores (1.0 mm diameter)
from the selected representative tumor areas were
punched out of the sample tissue blocks and embedded
into a new paraffin array block using a tissue microar-
rayer (Beecher Instruments, Woodland, CA,
USA). On-slide control tissues (tonsil and gallbladder)
were used.
PD-L1 immunohistochemistry
PD-L1 expression analysis was performed using three
different antibodies against PD-L1 (clone 28–8 (Abcam
plc, Cambridge, UK), clone SP142 (Linaris GmbH, Dos-
senheim, Germany), and clone SP263 (Roche AG, Rotk-
reuz, Switzerland)). In brief, 3 μm sections of the TMA
were deparaffinized, pre-treated with an antigen retrieval
buffer (Tris/Borat/EDTA, pH 8.4; Ventana, Roche) and
stained using an automated device (Ventana Benchmark
Ultra, Roche). Dilutions were as follows: 1:100 for anti-
body 28–8, 1:25 for antibody SP142, and a ready-to-use
kit for antibody SP263. Tumor cells and surrounding
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tumor stroma, including inflammatory infiltrates, were
scored separately. The number of cells showing mem-
branous staining was evaluated in percentage. According
to the German consensus recommendations for
immunohistochemical evaluation of PD-L1, any positiv-
ity was defined as ≥1% of positive cells having at least
weak membranous staining [10]. Tumor cells with pure
cytoplasmic staining were scored negatively. Figures
Table 1 Clinicopathological characteristics of the cholangiocarcinoma cohort
All cases PD-L1 (< 1%) PD-L1 (≥1%) p-value
Number (%) 170 (100) 151 (89) 19 (11)
Age Range (years) 31–91 31–91 34–78 0.886 *
Median (years) 63 63 66
<Median (total) 85 (50) 76 (45) 9 (5) 1.000 **
>Median (total) 85 (50) 75 (44) 10 (6)
Sex male 109 (64) 94 (55) 15 (9) 0.206 **
female 61 (36) 57 (34) 4 (2)
CCA subgroups iCCA 72 (42) 64 (38) 8 (5) 0.967 ***
pCCA 57 (34) 51 (30) 6 (4)
dCCA 41 (24) 36 (21) 5 (3)
UICC stage# UICC 1 6 (4) 6 (4) 0 (0) 0.481 ***
UICC 2 62 (36) 56 (33) 6 (4)
UICC 3 45 (26) 37 (22) 8 (5)
UICC 4 16 (9) 14 (8) 2 (1)
NA 41 (24) 38 (22) 3 (2)
pT T1 21 (12) 19 (11) 2 (1) 0.183 ***
T2 91 (54) 83 (49) 8 (5)
T3 44 (26) 39 (23) 5 (3)
T4 14 (8) 10 (6) 4 (2)
pN N0 53 (31) 49 (29) 4 (2) 0.267 **
N1 72 (42) 61 (36) 11 (6)
NX 45 (26) 41 (24) 4 (2)
M M0 153 (90) 136 (80) 17 (10) 1.000 **
M1 16 (9) 15 (9) 1 (1)
NA 1 (1) 0 (0) 1 (1)
G G1 8 (5) 6 (4) 2 (1) 0.135 ***
G2 121 (71) 111 (65) 10 (6)
G3 41 (24) 34 (20) 7 (4)
L L0 86 (51) 78 (46) 8 (5) 0.474 **
L1 84 (49) 73 (43) 11 (6)
V V0 125 (74) 111 (65) 14 (8) 1.000 **
V1 45 (26) 40 (24) 5 (3)
Pn Pn0 97 (57) 87 (51) 10 (6) 0.807 **
Pn1 73 (43) 64 (38) 9 (5)
R R0 76 (45) 63 (37) 13 (8) 0.109 ***
R1 56 (33) 53 (31) 3 (2)
R2 12 (7) 11 (6) 1 (1)
Rx 26 (15) 24 (14) 2 (1)
* Mann-Whitney U-test; ** Fisher’s exact test; *** Chi-square test
# Cases with pNX had no lymph nodes resected, therefore, UICC status could not be assessed
iCCA intrahepatic cholangiocarcinoma, pCCA perihilar cholangiocarcinoma, dCCA distal cholangiocarcinoma, NA not available
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were created using Inkscape (v.0.91, Free Software Foun-
dation, Inc., Boston, USA) and R (www.r-project.org,
v.3.2.5, Free Software Foundation).
Statistical analyses
Equally distributed continuous variables were analyzed
by Student’s t-test and unequally distributed variables by
Wilcoxon-Mann-Whitney test. Distribution data were
analyzed by Fisher’s exact test or χ2, where appropriate.
Cohen’s statistic was performed to test for agreement.
κ-values from 0.00 to 0.20 were considered as slight
agreement, from 0.21 to 0.40 fair agreement, from 0.41
to 0.60 moderate agreement, from 0.61 to 0.80 substan-
tial agreement and from 0.81 to 1.00 almost perfect
agreement. OS was analyzed using the Kaplan–Meier
method, with a log-rank test to test for significance. All
tests were performed in R programming language and
R-Studio (v.0.98.507, Affero General Public License,
Boston, USA). Plots were created by R-packages: ggplot2
(v. 2.1.0), and survival (v.2.37–7). P-values ≤0.05 were
considered significant.
Results
PD-L1 immunohistochemistry in the cholangiocarcinoma
cohort using three different antibodies
The complete CCA cohort (n = 170) was analyzed
three-times independently by PD-L1 immunohistochem-
istry employing three different PD-L1 antibodies (28–8,
SP142 and SP263, Fig. 1). Due to floating or rolling of
tissue cores, all three PD-L1 antibody clones could be
evaluated in all but one CCA patient (169 out of 170,
drop-out rate: < 1%). All three different CCA subtypes, i.
e. iCCA, pCCA and dCCA were analyzed separately.
PD-L1 antibody displaying the highest positivity rate in
CCA was clone SP263 (19/170, 11%, see Table 2). De-
tailed staining results of clone SP263, including CCA
A B C
D E F
G H I
Fig. 1 Examples of PD-L1 staining in a representative intrahepatic cholangiocarcinoma. The different staining characteristics of PD-L1 clones 28–8,
SP142 and SP263 are displayed. In the first row, tumor cells show membranous positivity of few tumor cells with antibody clones 28–8 (a) and
SP263 (c), but not with clone SP142 (b). In the second row, stromal inflammatory cells show membranous PD-L1 expression with all three
antibody clones (d-f), while tumor cells are negative. In the third row, all samples are negative, both in tumor and stromal cells, and with all three
PD-L1 antibodies (g-i). Original magnification: 200x, PD-L1 positive tumor cells are highlighted by black arrows, PD-L1 positive stromal cells are
highlighted by black triangles
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subtype specific evaluation and separated results for
tumor and stromal cells, are summarized in Table 2. Gen-
erally, more cases showed PD-L1 positivity in stroma than
in tumor cells (p < 0.01). On-slide control tissues exhibited
the following staining pattern: crypt epithelium of tonsils
showed strong membranous immunoreactivity and
immune cells in germinal centers were weakly positive, as
expected; gallbladder epithelium was negative and occa-
sionally immune cells in stromal tissue were positive
(Additional file 1: Figure S1).
PD-L1 immunohistochemistry in the cholangiocarcinoma
cohort and agreement between different PD-L1
antibodies
To test whether the PD-L1 antibodies 28–8, SP142 and
SP263 showed similar staining characteristics, agreement
between all three clones in tumor and stroma cells was
determined. Whereas clone 28–8 and SP263 were positive
in a similar number of tumor samples (8 (5%) in iCCA, 6
(4%) in pCCA and 5 (3%) in dCCA), SP142 exhibited tu-
moral positivity in only two cases. Interestingly, agreement
between 28-8 and SP263 in tumor cells was only moderate
(κ = 0.44), although the amount of positive tumor samples
was similar (11% each). Agreement of SP142 and the other
two clones was rather poor (κ = 0.13 [28-8] and κ = 0.11
[SP263]). Overall agreement of the three PD-L1 clones in
tumor cells was fair (κ = 0.25).
In stroma cells, clones 28–8, SP142 and SP263 were
positive in 31, 40 and 61% of cases, respectively. Agree-
ment between the three clones ranged from fair to sub-
stantial (κ = 0.37 to κ = 0.70). A summary for agreement
values is provided in Table 3.
PD-L1 status in correlation with clinicopathological data
of the cholangiocarcinoma cohort
Correlation analyses with clinicopathological data includ-
ing patient survival were conducted based on the staining
results of the antibody with the highest rate of positivity
(clone SP263). Overall survival data and PD-L1 staining
was available for 141 patients. Testing different cut-offs of
PD-L1 expression in association with patient survival
showed differences by trend in none vs any PD-L1 expres-
sion, and even more significant results using the cut-off of
> 5% PD-L1-positive tumor cells, while all other
pre-selected cut-offs were not statistically significant
(Additional file 2: Table S1). PD-L1 expression in > 5% of
tumor cells was associated with shortened patient overall
survival p < 0.001), whereas stromal PD-L1 expression
was not associated with any difference in patient survival
(p = 0.89) (Fig. 2). Stratification of clinicopathological vari-
ables using this cut-off is displayed in detail in Table 1.
CCA subtype specific analysis for PD-L1 expression in as-
sociation with patient survival showed decreased overall
survival rates in iCCA patients with PD-L1 positivity in >
5% of tumor cells (p = 0.02, Fig. 3b) and decreased overall
survival rates by trend in pCCA patients with PD-L1 posi-
tivity in > 5% of tumor cells (p = 0.06, Fig. 3d). PD-L1 ex-
pression in stroma cells was not associated with
differences in survival of CCA patients. Correlation of
PD-L1 status with all other clinicopathological data
showed no significant association.
Discussion
PD-L1 inhibitors have emerged as a novel and highly ef-
fective treatment option in a subset of cancer patients.
Recent data suggests, that PD-L1 testing by immunohis-
tochemistry prior to immunotherapy may be used to se-
lect patients who will most likely respond to therapy
with PD-L1 inhibitors [19, 20] and has therefore been
approved as companion diagnostic tests for therapeutic
anti-PD-1 antibodies in lung, kidney and urothelial car-
cinoma, as well as in malignant melanoma [6–8, 20]. As
many aspects of PD-L1 testing in association with CCA
have not been addressed systematically so far, we con-
ducted this study i) to evaluate the expression levels of
PD-L1 in CCA ii) to compare three different and
Table 2 PD-L1 expression in cholangiocarcinoma subtypes (tumor and stromal cells; PD-L1 antibody clone: SP263)
Tumor subgroups Tumor Stroma
Positive Negative Positive Negative
iCCA, n = 72
n (%) 8 (11) 64 (89) 22 (31) 50 (69)
% cells, median (range) 15 (5–30) n.a. 5 (1–40) n.a.
pCCA, n = 57
n (%) 6 (11) 51 (89) 23 (40) 34 (60)
% cells, median (range) 10 (5–80) n.a. 5 (2–30) n.a.
dCCA, n = 41
n (%) 5 (12) 36 (88) 25 (61) 16 (39)
% cells, median (range) 10 (5–30) n.a. 5 (1–30) n.a.
iCCA intrahepatic cholangiocarcinoma, pCCA perihilar cholangiocarcinoma, dCCA distal cholangiocarcinoma, n.a. not applicable
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Table 3 PD-L1 agreement in tumor and stromal cells of the cholangiocarcinoma cohort
*One CCA sample could not be evaluated for all three antibody clones due to technical reasons
Fig. 2 PD-L1 status in correlation with overall survival in cholangiocarcinoma patients. PD-L1 immunohistochemistry results using clone SP263 were
correlated with overall survival of CCA patients. Kaplan-Meier curves show a trend of decreased overall survival in CCA patients with any PD-L1 positivity in
tumor cells (p = 0.09; a). Significant decreased overall survival rates are seen in CCA patients with PD-L1 positivity in > 5% of tumor cells (p < 0.001; b). PD-L1
positivity in stromal cells has no impact on overall survival of CCA patients in none vs any (p = 0.89; c) or testing the cut-off of 5% (p = 0.69; d)
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commonly used antibodies against PD-L1 (clones 28–8,
SP142 and SP263) and iii) to correlate PD-L1 expression
levels with clinicopathological data, including overall
survival.
A summary of the previous studies on PD-L1 expres-
sion in CCA that are PubMed-listed is highlighted in
Table 4. The results obtained in these studies are highly
heterogeneous, ranging from 4 -100% PD-L1 positive
cases in iCCA, and 8 - 43% PD-L1 positive cases in extra-
hepatic CCA, including pCCA and dCCA. To date, the
largest single investigation comprises tissue samples of 99
CCA patients [21]. While earlier studies reported rela-
tively high positivity rates, newer investigations could not
confirm these high PD-L1 positivity rates in CCA. In our
study, a total of 170 cancer samples, including 72 iCCAs,
57 pCCAs and 41 dCCAs were analyzed using a
systematic tissue microarray approach. In agreement with
the studies from 2017, we here report PD-L1 positivity in
CCA tumor cells in 5%, 4%, and 3% of iCCA, pCCA and
dCCA, respectively, which is in line with the study of Sato
et al. and among the lowest rates published to date. We
hypothesize that the low rate of positive cases may be due
to the different anti-PD-L1 clones and evaluation proce-
dures used in the other studies. Furthermore, a smaller
histological tumor area as a consequence of the usage of
TMA could have contributed to the comparably low
Fig. 3 PD-L1 status in correlation with patient overall survival in cholangiocarcinoma subtypes. PD-L1 immunohistochemistry (clone SP263) results are
correlated with overall survival of CCA patients, stratified by CCA subtypes. In intrahepatic CCA (iCCA), Kaplan-Meier curves show no significant overall
patient survival difference in correlation with none vs any PD-L1 positivity in tumor cells (a), while significant decreased overall survival rates are seen
in iCCA patients with PD-L1 positivity in > 5% of tumor cells (p = 0.024); (b)). In perihilar CCA (pCCA), Kaplan-Meier curves show no significant overall
patient survival difference in correlation with none vs any PD-L1 positivity in tumor cells (c), while by trend decreased overall survival rates are in pCCA
patients with PD-L1 positivity in > 5% of tumor cells (p = 0.060; (d)). PD-L1 positivity in distal CCA (dCCA) has no impact on overall patient survival in
none vs any (e) or testing the cut-off of 5% (f)
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PD-L1 positivity rate in this study. We employed TMAs
in order to standardize the staining procedure as much as
possible among all cases. Inherent to the use of TMAs,
there is always a possible selection bias, as it is not entirely
clear if the extracted cancer regions are representative of
the whole tumor for each given test. In this regard, it is es-
pecially important to note that PD-L1 is often only focally
positive and that a positive staining has been described to
be more likely at the invasion front of the tumor [22]. We
tried to avoid this shortcoming by punching ≥4 cores of
different tumor sites of each CCA to assure the best pos-
sible representation for each tumor. However, a bias
resulting from the usage of TMAs cannot entirely be
excluded.
The differences in the percentage of positive samples
can potentially be explained by the usage of different
PD-L1 clones among the studies mentioned. The impact
of using different PD-L1 clones is underlined by a recent
study from the „Blueprint PD-L1 IHC Assay Compari-
son Project“, which demonstrated that the clones 28–8,
22C3 and SP263 show a similar proportion of positive
tumor cells, whereas SP142 stains a lower proportion of
tumor cells [10, 23]. In this study, we could confirm
these findings for CCA, as with the clone SP142 only
two cases were positive, while using the clones 28–8 and
SP263, 18, respectively, 19 tumors were positive. While
the results obtained with clone 28–8 and SP263 showed
moderate agreement (κ = 0.44, p < 0.01), the agreement
of 28–8 with SP142, and of 28–8 with SP263 were rather
poor (κ = 0.13 and κ = 0.11, p < 0.01). However, this re-
sult could be partly caused by heterogeneity of PD-L1
expression which cannot be accounted for by the use
of TMAs in this study. Moreover, due to the fact that in
most of the reported studies, clones were used that were
not included in our PD-L1 antibody panel, it is difficult
to compare the given results. Furthermore, the PD-L1
antibody clones used in most of the reported studies
were also not included in a current German PD-L1
harmonization study and are therefore not currently ad-
vised for routine use in Germany [10]. Nevertheless,
other antibody clones should be tested in order to find
the appropriate clone(s) to reliably detect patients that
will benefit from anti-PD-L1 therapy.
Up to now, it has generally been accepted in immuno-
histochemical PD-L1 testing that only membranous and
not cytoplasmic staining should be considered [10]. Of
the previous studies on PD-L1 testing in CCA (Table 4),
only five studies restricted their evaluation on membran-
ous staining of the tumor cells, and in one investigation
no comment about the mode of evaluation was made
[21, 22, 24–28]. Thus, the results obtained by Ye et al.
and Ma et al. cannot be compared to the other studies,
including our own. It is also currently recommended to
score only the proportion of positive cells, regardless of
their intensity, as it became evident that this represents
the only relevant parameter for predicting response to
anti-PD-L1 therapy [10]. Interestingly, the amount of
positive tumor cells seems to correlate with response to
therapy in other cancer types [19, 29]. Some authors use
the H-score, which consists of multiplication of intensity
and percentage of positive cells. This approach is debat-
able, as the H-score is probably not an ideal scoring sys-
tem for PD-L1 positivity. For example, ≥25% cells
stained with low intensity and ≥ 9% of cells stained with
strong intensity would classify for overall positivity based
on the H-score. Compared to many clinical trials which
require only ≥1% of tumor cells to have membranous
staining for positivity, the H-score defines a comparably
Table 4 Meta-analysis of PubMed listed studies about PD-L1 immunohistochemistry in cholangiocarcinoma
Study n= Subtype PD-L1
clone
Inflammatory cells, n/
n (%)
Tumor cells, n/n
(%)
Cut-off Evaluation criteria
Ye et al., 2009 31 iCCA 28–8 n.a. 31/31 (100) H-scorea, no cut-off described cytoplasmatic +
membranous
Gani et al., 2016 54 iCCA 5H1 31/54 (57) 39/54 (72) % positive cells (> 5%) membranous
Sabbatino et al., 2016 27 iCCA 22C3 27/27 (100) 8/27 (30) H-scorea (> 25) membranous
Sato et al., 2017 68 iCCA,
eCCA
28–8 n.a. 1/23 (4)
4/45 (8)
% positive cells (< 5, > 5, >
10%)
n.a.
Ma et al., 2017 70 eCCA EPR1161 37/70 (53) 30/70 (43) Immunohistochemical Score*:
> 3
cytoplasmatic +
membranous
Fontugne et al., 2017 99 iCCA,
pCCA
E1L3N 31/58 (53)
15/41 (37)
5/58 (9)
4/41 (9)
Strong staining in > 5% of
tumor cells
membranous
Sangkhamanon et al.,
2017
46 n.a. 5H1 n.a. 32/46 (70) > 1% positive tumor cells membranous
Walter et al., 2017 69 pCCA
dCCA
E1L3N 12/40 (30)
9/29 (31)
4/40 (10)
4/29 (14)
H-scorea (> 3) membranous
dCCA distal cholangiocarcinoma, eCCA extrahepatic cholangiocarcinoma, iCCA intrahepatic cholangiocarcinoma, pCCA perihilar cholangiocarcinoma.a
Immunohistochemical scoring system: percentage of cells with weak staining × 1 + percentage of cells with moderate staining × 2 + percentage of cells with
strong staining × 3 = H-Score *Immunohistochemical scoring system: Stained cells (0:< 5%,1:5–25%, 2:26–50%,3:> 50%) x intensity (1+, 2+, 3+) , n.a., not available
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high cut-off. Regardless, the immunohistochemical
scores that include staining intensity have been applied
in a substantial number of studies of our meta-analysis
in Table 4. As we set our cut-off to ≥1% positive tumor
cells, one would expect the percentage of positive cases
in our study to be higher than in the other three investi-
gations. However, we could not detect membranous
PD-L1 positivity on tumor cells in the majority of CCA
samples. Various clinicopathological variables have been
associated with PD-L1 positivity, including venous inva-
sion [25], nodal metastases [26], high tumor grade [25]
and high clinical stage [28]. However, we could not con-
firm these findings in this study by correlating PD-L1
status with clinicopathological data of our CCA patients.
In a recent meta-analysis involving more than 16,000
patients from 97 eligible studies on solid tumors, it was
shown that PD-L1 expression assessed by immunohisto-
chemistry significantly correlated with decreased over-
all and disease-free survival rates of patients [17]. This
could be due to the fact that high PD-L1 levels have
been shown to reduce T-cell function and to weaken the
host’s immune response against the tumor [1]. In this re-
gard, previous studies demonstrated the association of
high PD-L1 expression and decreased survival rates also
in CCA [22, 24, 26]. However, other investigators could
not confirm this finding [25, 28]. Our data corrobates
the findings of PD-L1 associated decreased overall sur-
vival in CCA patients. Additionally, using a PD-L1 ex-
pression cut-off of > 5% tumor cells, PD-L1 expression
displays some prognostic stratification power in CCA
patients (p < 0.001; Fig. 2b). Notably, prognostic signifi-
cance was only detected using the cut-off of 5% of
PD-L1 positive tumor cells. Whether PD-L1 positive
CCAs show better response to anti-PD-L1 treatment
and whether one clone is superior to reliably identify
these patients is not clear based on the available data.
This question should be addressed in future clinical tri-
als. We did not detect a prognostic impact of PD-L1
positive stromal cells. However, detailed characterization
of PD-L1 positive stromal cells merit future investiga-
tions. In addition, the question of whether specific stro-
mal cells may predict the response to novel therapeutic
approaches represents an interesting task for future
functional studies of the stromal compartment in CCA.
Conclusions
Here, we report in a large and well-characterized cohort
of non-liver fluke associated CCAs that the frequency of
PD-L1 positive CCAs is low, employing stringent immu-
nohistochemical PD-L1 testing guidelines. Apart from an
association of decreased overall survival in patients with
PD-L1 positive tumors, no significant association of
PD-L1 status with any other clinicopathological variable
of CCA patients was detected. Additionally, we showed
that the selection of appropriate PD-L1 antibodies and
careful evaluation of immunohistochemical staining pat-
terns have a great impact on PD-L1 testing in CCA. We
hope that our study paves the way for clinical trials that
are clearly required to investigate the effects of PD-L1 tar-
geted immunotherapy in CCA patients.
Additional files
Additional file 1: Figure S1. Example of a typical staining pattern of
on-slide control tissues (PD-L1, SP263). Tonsillary crypt epithelium showed
strong membranous immunoreactivity (black triangle), while immune
cells in germinal centers were weakly positive (black arrow, A). Gallblad-
der epithelium (black triangle) was negative but occasionally few immune
cells were positive (black arrow, B). (PPTX 2692 kb)
Additional file 2: Table S1. Clinicopathological characteristics of the
CCA cohort and comparison of patients with PD-L1 positive tumor cells
in ≤5% or > 5%. A detailed overview on the clinicopathological character-
istics of CCA exhibiting ≤5% or > 5% PD-L1 positive tumor cells is given.
(XLSX 11 kb)
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